These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 28555943

  • 1. Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
    Shoji H, Yoshio S, Mano Y, Doi H, Sugiyama M, Osawa Y, Kimura K, Arai T, Itokawa N, Atsukawa M, Aoki Y, Fukai M, Taketomi A, Mizokami M, Kanto T.
    Int J Cancer; 2017 Sep 01; 141(5):1011-1017. PubMed ID: 28555943
    [Abstract] [Full Text] [Related]

  • 2. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T, Palmer DH, Cheng AL, Hocke J, Loembé AB, Yen CJ.
    Liver Int; 2017 Jul 01; 37(7):1047-1055. PubMed ID: 28066978
    [Abstract] [Full Text] [Related]

  • 3. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
    Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H.
    PLoS One; 2016 Jul 01; 11(1):e0146456. PubMed ID: 26745625
    [Abstract] [Full Text] [Related]

  • 4. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V.
    Eur J Radiol; 2016 Jan 01; 85(1):103-112. PubMed ID: 26724654
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
    Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H, Shimose S, Shirono T, Koga H, Torimura T, Kurume Liver Cancer Study Group of Japan.
    Cancer Med; 2015 Dec 01; 4(12):1836-43. PubMed ID: 26471348
    [Abstract] [Full Text] [Related]

  • 6. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.
    Liver Int; 2013 Jul 01; 33(6):950-7. PubMed ID: 23601249
    [Abstract] [Full Text] [Related]

  • 7. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    Dig Dis; 2014 Jul 01; 32(6):705-10. PubMed ID: 25376287
    [Abstract] [Full Text] [Related]

  • 8. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
    Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T, Kurume Liver Cancer Study Group Of Japan.
    Oncotarget; 2016 Sep 27; 7(39):64400-64409. PubMed ID: 27462865
    [Abstract] [Full Text] [Related]

  • 9. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK, Park SY, Tak WY, Kweon YO, Kim BS, Lee CH.
    Clin Mol Hepatol; 2016 Mar 27; 22(1):160-7. PubMed ID: 27044767
    [Abstract] [Full Text] [Related]

  • 10. Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival.
    Nakamura Y, Kawaoka T, Higaki T, Fukumoto W, Honda Y, Iida M, Fujioka C, Kiguchi M, Aikata H, Chayama K, Awai K.
    Eur J Radiol; 2018 Jan 27; 98():41-49. PubMed ID: 29279169
    [Abstract] [Full Text] [Related]

  • 11. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND, Marshall VD, Singal AG, Nathan H, Lok AS, Balkrishnan R, Shahinian V.
    Hepatology; 2017 Jan 27; 65(1):122-133. PubMed ID: 27770556
    [Abstract] [Full Text] [Related]

  • 12. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S.
    Oncologist; 2014 Apr 27; 19(4):394-402. PubMed ID: 24652387
    [Abstract] [Full Text] [Related]

  • 13. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W.
    BMC Res Notes; 2015 Oct 26; 8():609. PubMed ID: 26502722
    [Abstract] [Full Text] [Related]

  • 14. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
    Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH.
    Medicine (Baltimore); 2015 Apr 26; 94(14):e688. PubMed ID: 25860213
    [Abstract] [Full Text] [Related]

  • 15. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cho HJ, Kim SS, Nam JS, Oh MJ, Kang DR, Kim JK, Lee JH, Kim B, Yang MJ, Hwang JC, Lim SG, Shin SJ, Lee KM, Yoo BM, Lee KJ, Cho SW, Cheong JY.
    Cytokine; 2017 Jul 26; 95():118-125. PubMed ID: 28260649
    [Abstract] [Full Text] [Related]

  • 16. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
    Jeong SW, Jang JY, Shim KY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim JH.
    Gut Liver; 2013 Nov 26; 7(6):696-703. PubMed ID: 24312711
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
    Park JG.
    Clin Mol Hepatol; 2015 Sep 26; 21(3):287-94. PubMed ID: 26527250
    [Abstract] [Full Text] [Related]

  • 18. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
    Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    Dig Dis; 2014 Sep 26; 32(6):733-9. PubMed ID: 25376291
    [Abstract] [Full Text] [Related]

  • 19. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
    Itokawa N, Atsukawa M, Tsubota A, Okubo T, Arai T, Nakagawa A, Kondo C, Iwakiri K.
    Int J Clin Oncol; 2016 Aug 26; 21(4):676-683. PubMed ID: 26701173
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
    Ziogas DC, Papadatos-Pastos D, Thillai K, Korantzis I, Chowdhury R, Suddle A, O'Grady J, Al-Khadimi G, Allen N, Heaton N, Ross PJ, Sarker D.
    Eur J Gastroenterol Hepatol; 2017 Jan 26; 29(1):48-55. PubMed ID: 27623000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.